UB Paderborn / Katalog / Suche / in CDI

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Annals of oncology, 2024-08, Vol.35 (8), p.707-717

2024

Volltextzugriff (PDF)

Choosing Wisely Campaign: Radiographic Surveillance in Triple Negative Breast Cancer

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E13-E13

2015

Volltextzugriff (PDF)

Toll-Like Receptor-9 Expression Does not Predict for Breast Cancer Specific Outcome in African-American Triple-Negative Breast Cancer Patients

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S815-S815

2014

Volltextzugriff (PDF)

‘Idiopathic’ eosinophilia with an Occult T-cell clone: Prevalence and clinical course

Leukemia research, 2007-05, Vol.31 (5), p.691-694

2007

Volltextzugriff (PDF)

333P Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)

Annals of oncology, 2023-10, Vol.34, p.S316-S316

2023

Volltextzugriff (PDF)

191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)

Annals of oncology, 2022-09, Vol.33, p.S623-S624

2022

Volltextzugriff (PDF)

Abstract P1-05-25: Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-05-25

2017

Volltextzugriff (PDF)

Abstract OT3-06-06: A phase I/II study of preoperative letrozole, everolimus, and TRC105 in women with newly diagnosed local or locally advanced potentially resectable hormone-Receptor positive and Her2 negative breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT3-06-06-OT3-06-06

2018

Volltextzugriff (PDF)

Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

Annals of oncology, 2019-11, Vol.30, p.ix22

2019

Volltextzugriff (PDF)

Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

Annals of oncology, 2019-10, Vol.30, p.v167-v168

2019

Volltextzugriff (PDF)

453PD - Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

Annals of oncology, 2019-10, Vol.30, p.v167-v168

2019

Volltextzugriff (PDF)

A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Annals of oncology, 2024-05

2024

Volltextzugriff (PDF)

Abstract OT3-05-09: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (Maintain trial)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT3-05-09-OT3-05-09

2018

Volltextzugriff (PDF)

Abstract P1-15-02: Withdrawn

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-15-02

2019

Volltextzugriff (PDF)

Pelvic reconstruction of the retroperitoneum after abdominoperineal resection of the rectum using full-thickness skin grafts

Techniques in coloproctology, 2004-11, Vol.8 Suppl 1 (S1), p.s85-s88

2004

Volltextzugriff (PDF)

Abstract P1-04-01: Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P1-P1-04-01

2013

Volltextzugriff (PDF)

A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e13512-e13512

2009

Volltextzugriff (PDF)

Clinical outcomes and prognostic factors of hepatic arterial infusion (HAI) chemotherapy combination regimens in 202 patients with advanced cancer metastatic to the liver: The phase I program M. D. Anderson Cancer Center experience

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13101-e13101

2010

Volltextzugriff (PDF)

453PDSafety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy: Implications for Risk Assessment, Prevention and Treatment

Drug safety, 2010-03, Vol.33 (3), p.171-187

2010

Volltextzugriff (PDF)

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Nature cancer, 2022-02, Vol.3 (2), p.232

2022

Volltextzugriff (PDF)

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019

Clinical cancer research, 2015-06, Vol.21 (12), p.2771-2779

2015

Volltextzugriff (PDF)

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

The New England journal of medicine, 2016-07, Vol.375 (1), p.23-34

2016

Volltextzugriff (PDF)

Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes

Cancer immunology research, 2016-05, Vol.4 (5), p.390-399

2016

Volltextzugriff (PDF)

Adaptive Randomization of Neratinib in Early Breast Cancer

The New England journal of medicine, 2016-07, Vol.375 (1), p.11-22

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Choosing Wisely Campaign: Radiographic Surveillance in Triple Negative Breast Cancer

Toll-Like Receptor-9 Expression Does not Predict for Breast Cancer Specific Outcome in African-American Triple-Negative Breast Cancer Patients

‘Idiopathic’ eosinophilia with an Occult T-cell clone: Prevalence and clinical course

333P Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)

191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)

Abstract P1-05-25: Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer

Abstract OT3-06-06: A phase I/II study of preoperative letrozole, everolimus, and TRC105 in women with newly diagnosed local or locally advanced potentially resectable hormone-Receptor positive and Her2 negative breast cancer

Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

453PD - Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Abstract OT3-05-09: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (Maintain trial)

Abstract P1-15-02: Withdrawn

Pelvic reconstruction of the retroperitoneum after abdominoperineal resection of the rectum using full-thickness skin grafts

Abstract P1-04-01: Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019)

A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement

Clinical outcomes and prognostic factors of hepatic arterial infusion (HAI) chemotherapy combination regimens in 202 patients with advanced cancer metastatic to the liver: The phase I program M. D. Anderson Cancer Center experience

453PDSafety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy: Implications for Risk Assessment, Prevention and Treatment

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes

Adaptive Randomization of Neratinib in Early Breast Cancer

Suchergebnisse filtern